8-K: Evolus Reports 15.5% Revenue Growth in Q1 2025, Driven by Jeuveau and Early Success of Evolysse

Evolus announces a 15.5% increase in global net revenue for Q1 2025, reaching $68.5 million, and reaffirms its full-year revenue guidance of $345 million to $355 million.

Summary

• Evolus, Inc. reported its financial results for the first quarter ended March 31, 2025.
• Global net revenue for Q1 2025 reached $68.5 million, a 15.5% increase compared to Q1 2024.
• The company experienced a GAAP operating loss of $15.2 million and a non-GAAP operating loss of $5.5 million for the quarter.
• Evolus reaffirmed its 2025 net revenue guidance of $345 million to $355 million.
• Evolysse and Estyme injectable HA gels are expected to contribute 8% to 10% of total revenue for the full year.
• The company anticipates achieving positive non-GAAP operating income on a consolidated basis for the full year 2025, with revenue contribution weighted toward the second half of the year, resulting in our non-GAAP operating income being generated in Q4 2025.
• Evolus expects total net revenue of at least $700 million by 2028, representing a compound annual growth rate of 27% from 2024.
• The company aims to achieve non-GAAP operating income margins of at least 20% by 2028.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and the successful launch of a new product. However, the operating losses and decrease in cash reserves temper the overall sentiment.

Positives

• The company achieved a 15.5% increase in revenue compared to the same quarter last year.
• Jeuveau continues to experience sustained demand and market share gains.
• The launch of Evolysse has shown promising early results.
• The Evolus Rewards program is experiencing significant growth and engagement.
• The company reaffirmed its revenue guidance for 2025.
• Evolus is on track to achieve positive non-GAAP operating income for the full year 2025.
• The company has a clear growth strategy with revenue targets for 2028.

Negatives

• The company reported a GAAP operating loss of $15.2 million for the first quarter of 2025, compared to $8.9 million in the first quarter of 2024.
• Non-GAAP operating loss was $5.5 million compared to $0.9 million in the first quarter of 2024.
• Cash and cash equivalents decreased from $87.0 million on December 31, 2024, to $67.9 million on March 31, 2025.

Risks

• The company's ability to comply with the terms and conditions in the Medytox Settlement Agreements.
• The company's ability to fund future operations or obtain financing.
• Unfavorable global economic conditions, including trade disputes and tariffs, could impact consumer discretionary spending.
• Customer and consumer adoption of Jeuveau and Evolysse may not meet expectations.
• The company's ability to successfully launch and commercialize products in new markets is subject to risks.
• The company's reliance on Symatese to achieve and/or maintain regulatory approval for the Evolysse HA gel products in the U.S.

Future Outlook

Evolus expects total net revenues for the full-year 2025 to be between $345 million and $355 million, representing 30% to 33% growth over 2024 results. The company anticipates achieving positive non-GAAP operating income on a consolidated basis for the full-year 2025 and expects total net revenue of at least $700 million by 2028.

Management Comments

• 'Coming off a record year, we enter 2025 with strong momentum,' said David Moatazedi, President and Chief Executive Officer of Evolus.
• Moatazedi stated that the company gained meaningful market share and delivered 15.5% year-over-year growth in Q1 2025.
• Moatazedi noted that early feedback from customers on Evolysse has been overwhelmingly positive.
• Moatazedi expressed confidence in reiterating the full-year 2025 revenue guidance.

Industry Context

Evolus is operating in the competitive aesthetics market, focusing on neurotoxins and hyaluronic acid gels. The company's growth is driven by its flagship product Jeuveau and the recent launch of Evolysse. The company is aiming to capture a larger share of the market by offering a superior value proposition and expanding its product portfolio.

Comparison to Industry Standards

• Evolus competes with established players in the aesthetics market such as Allergan (maker of Botox and Juvederm) and Galderma (maker of Dysport and Restylane).
• Evolus's strategy of focusing on a value proposition with Jeuveau aims to capture market share from premium-priced products like Botox.
• The company's expansion into hyaluronic acid gels with Evolysse positions it to compete with Juvederm and Restylane in the dermal filler market.
• Achieving 30% to 33% revenue growth in 2025 would be a strong performance compared to the overall growth rate of the aesthetics market.

Stakeholder Impact

• Shareholders: The report provides information on the company's financial performance and future outlook, which can influence investment decisions.
• Employees: The company's growth and expansion plans may create new job opportunities.
• Customers: The launch of new products like Evolysse offers customers more choices in aesthetic treatments.
• Suppliers: Increased demand for Evolus's products may lead to higher order volumes for suppliers.
• Creditors: The company's financial performance affects its ability to meet its debt obligations.

Next Steps

• Continue expanding Jeuveau in the U.S.
• Scale Nuceiva internationally.
• Support the launch of Evolysse and Estyme injectable HA gels.
• Introduce Estyme in Europe through a limited experience program.
• Launch Evolysse Sculpt in 2026 and Evolysse Lips in 2027.

Key Dates

Keywords

Evolus, Jeuveau, Evolysse, Estyme, Neurotoxin, Hyaluronic Acid, Aesthetics, Revenue, Financial Results, Market Share